Dirk J de Jong
Overview
Explore the profile of Dirk J de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
2422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Te Groen M, Wijnands A, den Broeder N, de Jong D, van Dop W, Duijvestein M, et al.
Gut
. 2025 Jan;
74(4):547-556.
PMID: 39819862
Background: It remains unclear if the increased colorectal neoplasia detection rate in inflammatory bowel disease (IBD) by high-definition (HD) dye-based chromoendoscopy compared with HD white-light endoscopy is due to enhanced...
2.
van Linschoten R, Jansen F, Pauwels R, Smits L, Atsma F, Kievit W, et al.
Dig Dis Sci
. 2024 Apr;
69(6):2165-2174.
PMID: 38594435
Background: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn's...
3.
Koggel L, Reijm A, Lantinga M, de Jong D, Rodrigues-Pinto E, Spaander M, et al.
Gastrointest Endosc
. 2024 Feb;
99(6):1027-1031.e6.
PMID: 38316224
Background And Aims: A novel multisegmented esophageal fully covered self-expandable metal stent (FCSEMS) was designed to reduce stent migration, which is seen in up to 30% of patients. The goal...
4.
Jansen F, van Linschoten R, Kievit W, Smits L, Pauwels R, de Jong D, et al.
J Crohns Colitis
. 2023 Jun;
17(11):1771-1780.
PMID: 37310877
Background And Aims: We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical...
5.
Jansen F, Smits L, Thomas P, de Jong D, Kreijne J, van Dop W, et al.
Dig Dis Sci
. 2023 May;
68(7):2936-2945.
PMID: 37131100
Background: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs...
6.
van Linschoten R, Jansen F, Pauwels R, Smits L, Atsma F, Kievit W, et al.
Lancet Gastroenterol Hepatol
. 2023 Feb;
8(4):343-355.
PMID: 36736339
Background: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab...
7.
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
Derikx L, Lantinga M, de Jong D, van Dop W, Creemers R, Romkens T, et al.
J Crohns Colitis
. 2020 Oct;
15(4):529-539.
PMID: 33079178
Background And Aims: The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course, and outcomes of...
8.
Kreijne J, de Vries A, de Veer R, Bouma G, Dijkstra G, Voskuil M, et al.
Aliment Pharmacol Ther
. 2020 Apr;
51(12):1353-1364.
PMID: 32342997
Background: To timely detect myelotoxicity and hepatotoxicity, laboratory monitoring at 3-month intervals is advised throughout thiopurine maintenance treatment for IBD. However, reported incidence rates of myelotoxicity and hepatotoxicity in maintenance...
9.
Biemans V, van der Woude C, Dijkstra G, van der Meulen-de Jong A, Oldenburg B, de Boer N, et al.
Clin Pharmacol Ther
. 2019 Nov;
107(5):1189-1199.
PMID: 31677154
Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients...
10.
Kreijne J, de Veer R, de Boer N, Dijkstra G, West R, Moorsel S, et al.
Aliment Pharmacol Ther
. 2019 Jul;
50(4):407-415.
PMID: 31359480
Background: Low-dose thiopurine-allopurinol (LDTA) combination therapy is a commonly applied optimisation strategy in IBD patients with a skewed thiopurine metabolism. Aim: To assess continued LDTA maintenance treatment at annual intervals...